Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Arlington Financial Advisors LLC

Arlington Financial Advisors LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,020 shares of the biopharmaceutical company’s stock after purchasing an additional 915 shares during the quarter. Arlington Financial Advisors LLC’s holdings in Gilead Sciences were worth $4,343,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. D Orazio & Associates Inc. grew its holdings in shares of Gilead Sciences by 39.6% during the fourth quarter. D Orazio & Associates Inc. now owns 4,082 shares of the biopharmaceutical company’s stock worth $377,000 after buying an additional 1,158 shares in the last quarter. Kingsview Wealth Management LLC grew its stake in Gilead Sciences by 110.9% during the 4th quarter. Kingsview Wealth Management LLC now owns 42,014 shares of the biopharmaceutical company’s stock valued at $3,881,000 after acquiring an additional 22,091 shares in the last quarter. Apollon Wealth Management LLC raised its holdings in Gilead Sciences by 40.7% in the 4th quarter. Apollon Wealth Management LLC now owns 37,999 shares of the biopharmaceutical company’s stock valued at $3,510,000 after acquiring an additional 11,000 shares during the last quarter. Vest Financial LLC lifted its stake in Gilead Sciences by 14.6% in the 4th quarter. Vest Financial LLC now owns 5,989 shares of the biopharmaceutical company’s stock worth $553,000 after purchasing an additional 762 shares in the last quarter. Finally, NatWest Group plc acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $6,808,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $96.04 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $100.51. The firm has a market cap of $119.69 billion, a PE ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The company’s 50 day moving average is $92.97 and its two-hundred day moving average is $86.49.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the business posted $2.29 earnings per share. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock valued at $53,611,715 in the last quarter. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. BMO Capital Markets increased their price target on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Wells Fargo & Company lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Finally, Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.